Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 28.57%, near the low end of its 5-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
28.57%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.03%
median of 851 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Gain Therapeutics, Inc.
Market Cap
$71.87M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
28.57%
Market Cap
$72.36M
Gross Margin
60.78%
TTM Avg
57.02%
3Y Avg
54.79%
5Y Avg
56.72%
Market Cap
$69.75M
Gross Margin
49.30%
TTM Avg
49.08%
3Y Avg
46.18%
5Y Avg
47.39%
Market Cap
$74.56M
Gross Margin
85.89%
TTM Avg
77.06%
3Y Avg
82.88%
5Y Avg
71.27%
Market Cap
$68.32M
Gross Margin
100.00%
TTM Avg
-0.84%
3Y Avg
37.19%
5Y Avg
-61.56%
Market Cap
$68.18M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
Market Cap
$68.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$75.75M
Gross Margin
66.34%
TTM Avg
59.91%
3Y Avg
56.70%
5Y Avg
58.64%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.87M | 0.00% | 0.00% | 0.00% | 28.57% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.36M | 60.78% | 57.02% | 54.79% | 56.72% |
| Champions Oncology, Inc. (CSBR)vs › | $69.75M | 49.30% | 49.08% | 46.18% | 47.39% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $74.56M | 85.89% | 77.06% | 82.88% | 71.27% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.32M | 100.00% | -0.84% | 37.19% | -61.56% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.18M | 62.53% | 65.36% | 65.75% | 64.06% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.75M | 66.34% | 59.91% | 56.70% | 58.64% |
| iBio, Inc. (IBIO)vs › | $67.52M | 100.00% | 100.00% | 75.00% | 39.52% |
| Hyperfine, Inc. (HYPR)vs › | $76.48M | 51.41% | 47.75% | 37.98% | -14.72% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
